13.07.2015 Views

Evaluación de la inmunogenicidad y la capacidad protectora de la ...

Evaluación de la inmunogenicidad y la capacidad protectora de la ...

Evaluación de la inmunogenicidad y la capacidad protectora de la ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Lopes JD, Da-Mota GF, Carneiro CR, Gomes L, Costa e Silva Filho F. Evolutionaryconservation of <strong>la</strong>minin-binding proteins. Braz J Med Biol Res 1988; 21:1269-73.Lossick JG, Kent HL. Trichomoniasis: trends in diagnosis and management. Am J ObstetGynecol 1991;165:1217-22.Lubick KJ, Burgess DE. Purification and analysis of a phospholipase A2-like lytic factor ofTrichomonas vaginalis. Infect Immun 2004;72:1284-90.Lushbaugh WB, Blossom AC, Shah PH, Banga AK, Jaynes JM, Cleary JD, Finley RW.Use of intravaginal microbici<strong>de</strong>s to prevent acquisition of Trichomonas vaginalis infectionin Lactobacillus pretreated, estrogenized young mice. Am J Trop Med Hyg 2000;63, 284–9.Macura N, Zhang T, Casa<strong>de</strong>vall A. Depen<strong>de</strong>nce of macrophage phagocytic efficacy onantibody concentration. Infect Immun 2007;75:1909-15.Ma<strong>de</strong>iro da Costa RF, <strong>de</strong> Souza W, Benchimol M, Al<strong>de</strong>rete JF, Morgado-Díaz JA.Trichomonas vaginalis perturbs the junctional complex in epithelial cells. Cell Research2005;15:704-16.Magnus M, C<strong>la</strong>rk R, Myers L, Farley T, Kissinger PJ. Trichomonas vaginalis among HIVinfected women: are immune status or protease inhibitor use associated with subsequent T.vaginalis positivity? Sex Transm Dis 2003;30:839-43.Mal<strong>la</strong> N, Gupta I, Mahaja RC. Human trichomonosis. Ind J Med Microb. 2001;19:26-43.Mal<strong>la</strong> N, Yadav M, Gupta I. Kinetic of serum and local cytoquine profile in experimentalintravaginal trichomonosis induced with Trichomonas vaginals iso<strong>la</strong>tes from symtomaticand asymthomatic women. Parasite Immunol 2007;29:101-5.Martinez V, Caume E. Metronidazole: Pharmacology. Ann Dermatol Venereol2001;28:903-9.Mayer Z, Pe<strong>la</strong>k Z. Personal experience with SolcoTrichovac. Cesk Gynekol 1990;55:590-3.McClel<strong>la</strong>nd RS, Sangare L, Hassan WM, Lavreys L, Mandaliya K, Kiarie J, et al. Infectionwith Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis2007;195:698-702.McCluskie MJ, Davis HL. CpG DNA as mucosal adjuvant. Vaccine 1999,18:231–7.McGrory T, Garber GE. Mouse intravaginal infection with Trichomonas vaginalis and roleof Lactobacillus acidophilus in sustaining infection. Infect Immun 1992;60:2375-9.McGrory T, Meysick KC, Lemchuk-Favel LT, Garber GE. The interaction of Lactibacillusacidophillus and Trichomonas vaginalis in vitro. J Parasitol 1994;80:50-4.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!